Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Portfolio Pulse from Vandana Singh
The U.S. government announced negotiated prices for ten drugs under Medicare Part D, effective January 1, 2026, aiming to save $6 billion. Despite this, U.S. drug prices remain significantly higher than in other countries. Companies like Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, AstraZeneca, Novartis, Amgen, and Novo Nordisk are affected.
September 03, 2024 | 7:12 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Amgen's Enbrel priced at $2,355 under Medicare, but U.S. prices remain high compared to other countries.
The price for Enbrel is part of Medicare negotiations, but the impact on AMGN's stock is neutral due to high U.S. prices and expected minimal impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
AstraZeneca's Farxiga priced at $178.50 under Medicare, but U.S. prices remain high compared to other countries.
The price for Farxiga is part of Medicare negotiations, but the impact on AZN's stock is neutral due to high U.S. prices and expected minimal impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Bristol Myers Squibb's Eliquis price negotiated to $231 under Medicare, but U.S. prices remain high compared to other countries.
The negotiated price for Eliquis is part of a broader Medicare initiative, but the impact on BMY's stock is neutral as the U.S. prices remain high, and the company expects minimal impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Johnson & Johnson's drugs Xarelto, Stelara, and Imbruvica have new Medicare prices, but U.S. prices remain high compared to other countries.
The new Medicare prices for JNJ's drugs are part of a broader initiative, but the impact on JNJ's stock is neutral as U.S. prices remain high and the company expects minimal impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Eli Lilly's Jardiance price reduced by 66% to $197 under Medicare, but U.S. prices remain high compared to other countries.
The significant price reduction for Jardiance is part of Medicare negotiations, but the overall impact on LLY's stock is neutral due to high U.S. prices and expected minimal impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Merck's Januvia priced at $113 under Medicare, but U.S. prices remain high compared to other countries.
The negotiated price for Januvia is part of Medicare's efforts, but the impact on MRK's stock is neutral due to high U.S. prices and expected minimal impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Novo Nordisk's Fiasp price reduced by 76% to $119 under Medicare, but U.S. prices remain high compared to other countries.
The significant price reduction for Fiasp is part of Medicare negotiations, but the impact on NVO's stock is neutral due to high U.S. prices and expected minimal impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Novartis's Entresto price cut by 53% to $295 under Medicare, but U.S. prices remain high compared to other countries.
The significant price reduction for Entresto is part of Medicare negotiations, but the impact on NVS's stock is neutral due to high U.S. prices and expected minimal impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80